The Team
Mr Michael O’Rourke, CEO, Director

Michael O’Rourke, has been involved in “drug delivery” for over 30 years across Ophthalmology, Periodontal and Pulmonary markets including strategy development and global commercialization; previous companies include 3M Pharma, Pfizer, Alza, Chiron Vision, Bausch + Lomb and GrayBug. In 2009 Michael founded Scotia Vision Consultants advising ophthalmic companies on all aspects of commercialization and product development with a focus on anterior and posterior ocular drug delivery

Prior to establishing Scotia Vision Consultant in 2009, Michael was General Manager for the $200m Bausch + Lomb U.S. Pharmaceuticals division in Tampa FL with full P&L and operating responsibility, transforming the business to record levels of growth and managing 150 employees. Previously he pioneered new Bausch + Lomb global strategy divisions including Pharmaceutical, Drug Delivery and Surgical products in California and Rochester NY. Michael was CEO for the start up company GrayBug based in Johns Hopkins University (Baltimore, Maryland) where his accomplishments included the closure of an A2 round, securing 4 SBIR grants totalling $750K, developing an infra structure for business development deals and advancing pre clinical research programs in retina and glaucoma.

His ocular drug delivery experience includes launching the world’s first intra ocular drug delivery technology in Europe, Vitrasert®, and the world’s second, Retisert®, in the USA. Michael was the first European Marketing Director for Chiron Vision Europe. Additional experience includes Alza International (drug delivery) establishing their European division and launching the world’s first sustained release technology Actisite® treating periodontitis. At 3M Michael worked in both sales and marketing for new sustained release therapeutics and enhanced aerosol delivery technologies treating pulmonary disease.

Michael has managed 28 brands, led 13 product launches, structured/negotiated 12 strategic business deals and has been a team member in 18 device/drug approvals. Michael has both presented and published within ophthalmology at congresses and within respected journals. He is past Chairman of The Foundation Board for The Lions Eye Institute, guest speaker on strategic planning at the University of Tampa and was part time marketing lecturer at Trent University in Nottingham, UK.

He is a native of Scotland and has lived and worked in Europe, USA and Asia. In 2010 he became a member of the GlobalScot Business network; assisting Scottish based Life Science companies plan for USA market entry. He currently resides in Tampa, FL.

Dr Brian Levy, Scientific Advisor USA

Dr Brian Levy, is currently CEO of OcuNexus Therapeutics a Biopharm company developing novel and differentiated products in ophthalmology targeting Gap Junction Channel Modulation. Prior to OcuNexus he was Chief Medical Officer at Aerie Pharmaceuticals developing Rho Kinase Inhibitors for the lowering of IOP in patients with Glaucoma and prior to that Chief Operating Officer at Danube Pharmaceuticals a startup also developing a product for lowering of IOP. Before entering the startup world he was Corporate Vice President R&D and Chief Medical Officer at Bausch & Lomb for 15 years. At Bausch & Lomb he was responsible for 3 NDA’s for pharmaceuticals (Retisert, Zylet, Besivance) all FDA approved and currently in the market. Prior to Bausch & Lomb he was Associate Professor, Department of Ophthalmology at California Pacific Medical Center in San Francisco and prior to that in private practice in Toronto and a clinical investigator and consultant to the ophthalmic industry. He received a Doctor of Optometry degree from the University of California at Berkeley and a Master of Science in comparative anatomy and physiology of the eye at University of Waterloo in Canada.

Prof Clive Wilson, Scientific Advisor EU

Prof Clive Wilson, is the J. P. Todd Professor of Pharmaceutics at Strathclyde University in Glasgow and serves on the European Union Federation of Pharmaceutical Sciences teaching and overseas liaison committee. Major areas of research have been the study of the behaviour of drug formulations in man. He pioneered applications of scintigraphy in the study of physiological and patho-physiological effects on drug absorption following oral, nasal, pulmonary and ophthalmic delivery. In the university, his group collaborates with industry on ophthalmic drug delivery projects especially related to the behaviour of ocular implants. Recent new areas of interest include additive soft and hard matrix technologies for drug delivery, and several programmes in novel therapies for treating ulcerative colitis. Primary Teaching activities are in the field of Biopharmaceutics and formulation research.

Dr. Kieran Rooney, Board Chairman

Dr. Kieran Rooney, is a senior pharma/biotech professional with a successful 25 year career in drug discovery R&D, clinical drug development, business development and commercial management in the pharma/biotech sector. He has a proven track record in building and commercializing life science companies, including successfully developing and delivering commercial strategies through to company exit. In addition to Board-level experience in a variety of life science companies, he has closed multiple multinational licensing and investment deals.  He has broad scientific, commercial, technology and therapeutic experience across multiple franchises and business models in pharma/biotech. Kieran earned his doctorate in neuropharmacology from the University of Wales, and was a postdoctoral research fellow at the Universities of Nottingham & Bristol. He has a degree in pharmacy and is a member of the Royal Pharmaceutical Society of Great Britain.

Mr. Jim Sharkey, Director

Mr. Jim Sharkey, is an experienced ophthalmologist specialising in the treatment of Vitreo Retinal diseases at the Royal Victoria Hospital in Belfast. Jim studied medicine at the Queens University in Belfast and is a Fellow of The Royal College of Surgeons of Glasgow (Ophthalmology), The Royal College of Ophthalmologists. He also completed a Fellowship in Vitreo-Retinal Diseases and Surgery and Uveitis, Bascom Palmer Eye Institute, Miami, Florida, USA, 1993-94. He has pioneered the advancement of retina surgery and treatments in Northern Ireland since 1994 and is a member of the British Medical Association, the British and Eire Association of Vitreo-Retinal Surgeons and American Academy of Ophthalmology.

Dr. Thakur Raghu Raj Singh,  CSO, Co-Founder, Director

Dr. Raj Thakur, is a Senior Lecturer in Pharmaceutics, School of Pharmacy, Queen’s University Belfast. He holds a PhD in Drug Delivery, MSc in Pharmaceutical Sciences and Bachelors in Pharmacy. Dr. Thakur’s research interests lie in the design and physicochemical characterisation of advanced polymeric drug delivery systems for ocular applications. His research group has developed novel long-acting technologies including injectable implants, particulate-based systems and pre-formed implantable devices for delivery of a wide range of therapeutics to address ophthalmic conditions. He has authored over 132 scientific publications, including 43 full papers and two books. He has been an invited speaker at a number of national and international meetings. He is currently as acting as a Scientific Advisor to the editors of the J Pharmaceutical Sciences and editorial board member of a number of international journals.

Prof. David Jones, CSA, Co-Founder, Director

Prof. David Jones, is Professor of Biomaterial Science at Queen’s University Belfast and Pro-Vice-Chancellor for Education and Students. His research concerns the characterisation, formulation and engineering of pharmaceutical materials/dosage forms and biomedical devices. He is the author of two textbooks, 6 patents and over 400 research papers/communications and has been awarded the Lilly prize for pharmaceutical research and the British Pharmaceutical Conference Science Award. Professor Jones is both a Chartered Engineer and a Chartered Chemist and is an elected Fellow of the Pharmaceutical Society of Northern Ireland, a Fellow of the Institute of Materials, Minerals and Mining, a Fellow of the Royal Statistical Society, a Member of the Royal Society of Chemistry and a Member of the Institute of Engineers in Ireland. He is the Editor of the Journal of Pharmacy and Pharmacology and is a previous holder of the prestigious position of a Royal Society Industrial Fellow. He has been the founder and Director of two University-based Companies, Xiomateria and Carapacics, both concerned with the design and development of novel medical devices.